MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD
Xiangzhen Meng, Luo Wang, Xinlun Tian · 2026
Read MSCs/EVs-based therapy targeting DAD: research progress and future perspectives from ARDS and COVID-19 to RP-ILD by Xiangzhen Meng, Luo Wang, Xinlun Tian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13501695.txt.
Description
Xiangzhen Meng, Luo Wang, and Xinlun Tian present a 2026 review of cell and vesicle therapy aimed at diffuse alveolar damage, the core lung injury pattern behind several lethal conditions. That damage pattern, involving injured air sac walls, an inflammatory storm, and later scarring, drives acute respiratory distress syndrome, severe COVID-19, and rapidly progressive interstitial lung disease. Mesenchymal stromal cells and the tiny vesicles they shed have drawn attention for calming immunity, preventing cell death, repairing tissue, and limiting fibrosis.
The review organizes the field around the damage framework itself. Each stage is matched with the mechanisms by which the cells or their vesicles might intervene. The stages run from epithelial and endothelial barrier injury through inflammatory amplification to fibrotic remodelling, across the three diseases. The authors aim to move the field from scattered trials toward a mechanism-driven treatment paradigm and to give clinical use a firmer footing.
Catalog record
| CREATOR | Xiangzhen Meng, Luo Wang, Xinlun Tian |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40049 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |